Stephen E Kurtz

Title: The Innovations of Stephen E. Kurtz

Introduction

Stephen E. Kurtz is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of modified yeast cells for medical applications. With a total of 2 patents, his work focuses on creating innovative solutions for viral infections and cardiac conditions.

Latest Patents

Kurtz's latest patents include a modified strain of Saccharomyces cerevisiae that expresses the M.sub.2 protein of the influenza A virus. This invention allows for the detection of modulators of M.sub.2, which can be crucial in developing antiviral agents. The process involves treating the modified yeast cells with test substances and assessing their growth, where changes in growth indicate the presence of M.sub.2 modulators. Additionally, he has developed another modified Saccharomyces cerevisiae cell that expresses minK while lacking TRK1 and TRK2. This invention also includes a method for detecting modulators of minK, which can lead to advancements in anti-arrhythmic and anti-ischemic therapies.

Career Highlights

Stephen E. Kurtz is currently associated with Bristol-Myers Squibb Company, where he continues to innovate in the field of biotechnology. His work has the potential to impact the treatment of various viral and cardiac conditions significantly.

Collaborations

Kurtz has collaborated with notable colleagues such as Mark R. Krystal and Aron M. Knickerbocker, contributing to a dynamic research environment that fosters innovation.

Conclusion

Stephen E. Kurtz's contributions to biotechnology through his patents and collaborations highlight his role as a key inventor in the field. His work not only advances scientific understanding but also paves the way for new therapeutic options.